PARG

PARG INHIBITOR

Repress cancer growth and sensitize cancer cells to DNA damage therapy

 

Indications

Cancer

Mode Of Action

Inhibition of poly (ADP-ribose) glycohydrolase (PARG) enzyme

Main Advantages

  • Higher efficacy than PARP inhibitors, against a broader spectrum of cancer types.

Collaborators



Lady Davis Institute, Jewish General Hospital, McGill University


Testimonials

Disease Facts / Medical Need

  • Cancer is a devastating disease that is a major focus of academic and pharmaceutical research.

How This Target Works

PARG is an enzyme that plays a key role in DNA damage repair and in the transformation of normal cells to cancer cells, promoting their growth and invasive capability.

PARG is elevated in cancers of the breast, lungs, prostate, and acute lymphoblastic leukemia.

The inhibition of PARG aims to repress cancer growth and to sensitize cancer cells to DNA damage therapy

For more information

Kem Payza

Project Director

514-260-1079 kpayza@neomed.ca
© 2019 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia